Metropolitan Life Insurance Company (MetLife)’s NCR Voyix VYX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-41,637
| Closed | -$1.03M | – | 2701 |
|
|
2021
Q4 | $1.03M | Sell |
41,637
-668
| -2% | -$16.9K | 0.01% | 942 |
|
|
2021
Q3 | $1.01M | Sell |
42,305
-1,324
| -3% | -$34.4K | 0.01% | 939 |
|
|
2021
Q2 | $1.22M | Buy |
43,629
+3,582
| +9% | +$99.1K | 0.02% | 859 |
|
|
2021
Q1 | $932K | Buy |
40,047
+2,428
| +6% | +$53.4K | 0.01% | 987 |
|
|
2020
Q4 | $867K | Sell |
37,619
-872
| -2% | -$14.5K | 0.01% | 981 |
|
|
2020
Q3 | $523K | Sell |
38,491
-1,873
| -5% | -$22.3K | 0.01% | 1193 |
|
|
2020
Q2 | $429K | Sell |
40,364
-24,536
| -38% | -$281K | 0.01% | 1326 |
|
|
2020
Q1 | $705K | Sell |
64,900
-3,464
| -5% | -$59.5K | 0.01% | 853 |
|
|
2019
Q4 | $1.47M | Buy |
68,364
+1,047
| +2% | +$20.4K | 0.02% | 700 |
|
|
2019
Q3 | $1.3M | Buy |
67,317
+3,613
| +6% | +$69.8K | 0.02% | 713 |
|
|
2019
Q2 | $1.22M | Buy |
63,704
+238
| +0.4% | +$4.42K | 0.02% | 780 |
|
|
2019
Q1 | $1.06M | Buy |
63,466
+39
| +0.1% | +$646 | 0.02% | 848 |
|
|
2018
Q4 | $898K | Buy |
63,427
+230
| +0.4% | +$3.61K | 0.02% | 863 |
|
|
2018
Q3 | $1.1M | Sell |
63,197
-596
| -0.9% | -$10.6K | 0.02% | 883 |
|
|
2018
Q2 | $1.17M | Sell |
63,793
-1,006
| -2% | -$19K | 0.02% | 839 |
|
|
2018
Q1 | $1.25M | Sell |
64,799
-1,022
| -2% | -$21.5K | 0.02% | 793 |
|
|
2017
Q4 | $1.37M | Sell |
65,821
-129,385
| -66% | -$2.63M | 0.02% | 754 |
|
|
2017
Q3 | $4.49M | Buy |
195,206
+579
| +0.3% | +$13.3K | 0.03% | 639 |
|
|
2017
Q2 | $4.88M | Sell |
194,627
-2,663
| -1% | -$67.6K | 0.03% | 593 |
|
|
2017
Q1 | $5.53M | Buy |
197,290
+251
| +0.1% | +$6.88K | 0.04% | 527 |
|
|
2016
Q4 | $4.9M | Sell |
197,039
-771
| -0.4% | -$17.3K | 0.04% | 581 |
|
|
2016
Q3 | $3.91M | Sell |
197,810
-1,068
| -0.5% | -$21K | 0.03% | 681 |
|
|
2016
Q2 | $3.39M | Buy |
198,878
+15,571
| +8% | +$282K | 0.03% | 715 |
|
|
2016
Q1 | $3.37M | Sell |
183,307
-44,544
| -20% | -$639K | 0.03% | 700 |
|
|
2015
Q4 | $3.42M | Buy |
227,851
+1,548
| +0.7% | +$24.7K | 0.03% | 667 |
|
|
2015
Q3 | $3.16M | Sell |
226,303
-18,135
| -7% | -$302K | 0.02% | 716 |
|
|
2015
Q2 | $4.51M | Buy |
244,438
+1,017
| +0.4% | +$18.8K | 0.03% | 590 |
|
|
2015
Q1 | $4.41M | Buy |
243,421
+8,779
| +4% | +$153K | 0.03% | 586 |
|
|
2014
Q4 | $4.2M | Buy |
234,642
+2,608
| +1% | +$45.8K | 0.03% | 625 |
|
|
2014
Q3 | $4.76M | Buy |
232,034
+1,858
| +0.8% | +$37.7K | 0.03% | 530 |
|
|
2014
Q2 | $4.96M | Sell |
230,176
-7,322
| -3% | -$148K | 0.03% | 544 |
|
|
2014
Q1 | $5.33M | Buy |
237,498
+4,693
| +2% | +$99.7K | 0.04% | 501 |
|
|
2013
Q4 | $4.87M | Buy |
232,805
+1,415
| +0.6% | +$31.4K | 0.03% | 525 |
|
|
2013
Q3 | $5.62M | Buy |
231,390
+4,491
| +2% | +$100K | 0.04% | 441 |
|
|
2013
Q2 | $4.59M | Buy |
+226,899
| New | +$4.21M | 0.04% | 483 |
|
Other funds holding VYX
RRAM
EC
SBH
Metropolitan Life Insurance Company (MetLife)'s VYX Position: Q1 2022 in Review
Metropolitan Life Insurance Company (MetLife) sold out of NCR Voyix (VYX) in Q1 2022, closing a stake of 41,637 shares — an estimated $1.03M sold.
Metropolitan Life Insurance Company (MetLife) first reported a position in VYX in Q2 2013 and held it in 35 quarters. The position peaked at $5.62M in Q3 2013. 390 funds tracked by Wall St. Rank hold VYX as of Q1 2022.
- Metropolitan Life Insurance Company (MetLife) reported no remaining NCR Voyix position as of Q1 2022 after selling out during the quarter.
- Metropolitan Life Insurance Company (MetLife) sold 41,637 NCR Voyix shares in Q1 2022, an estimated $1.03M.
- Metropolitan Life Insurance Company (MetLife) first reported a position in NCR Voyix in Q2 2013 and held it in 35 quarters.
- Metropolitan Life Insurance Company (MetLife)'s NCR Voyix position peaked at $5.62M in Q3 2013.
- 390 funds tracked by Wall St. Rank held NCR Voyix as of Q1 2022.
Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q1 2022, filed 12 May 2022.